A systematic review of ustekinumab in the treatment of atopic dermatitis.
Ustekinumab, a human monoclonal IgG1 antibody targeting the p40-subunit shared by interleukin (IL)12 and IL-23, represents a potential treatment for atopic dermatitis (AD). We evaluated the efficacy and safety of ustekinumab in the treatment of AD. We reviewed the published literature by searching from PubMed, EMBASE, Web of Science and ClinicalTrial.gov then retrieved and analyzed several variables from patients records. Ten studies including eight cases and two RCT, comprising 107 patients, were included in the systematic review. Analysis all studies, a total of 58 patients (54.2%) gained an effective treatment with little adverse events. Ustekinumab is a well-tolerated and safe treatment with no significant difference in effect from placebo in patients with AD. Further, larger randomized controlled trials need to be conducted to identify a suitable regimen for AD and provide more evidence for clinical application.